



Antibacterial Activity of Germicide-P[®]: A Persulfate Based Detergent/Disinfectant on Some Hospital Isolates

Farzaneh Lotfipour^{a,b,*}, Mohammad Reza Nahaei^{b,c}, Morteza Milani^a, Vahid Javaherzadeh^c,
Amin Omrani^c, Navid Attar^{a,c}

^aFaculty of Pharmacy; ^bDrug Applied Research Center; ^cSchool of Medicine, Tabriz University of Medical Sciences, Tabriz, Iran

Abstract

A novel chemical detergent/disinfectant formulated based on persulfate salts, germicide P[®], is available for disinfection of surfaces and medical devices at the room temperature. Because of the resistance of hospital-resident microorganisms, the antimicrobial activity of this compound is evaluated in the present study. The tests conducted with this disinfectant included bactericidal tests against 25 clinical isolates of gram negative bacteria of *Escherichia coli*, *Pseudomonas aeruginosa* as well as 25 clinical isolates of gram positive bacteria of *Staphylococcus aureus* with and without 5% bovine serum albumin (BSA) as dirty condition. All of the experiments also performed using standard strains and serial dilution method applied to find minimum bactericidal concentration (MBC) of germicide P[®] against the selected bacteria at different exposure times. Also, to determine the ability of germicide P[®] for disinfection of surfaces, standard surface tests were conducted using all of the clinical isolates as well as standard strains. According to the *in vitro* results of the tests, germicide P[®] found to be a promising product with the MBC of 1/10 after 5 min. against all of the tested bacteria at the room temperature, however, the results of the surface tests indicated that a significant reduction in the efficacy of germicide P[®] was observed and the MBC dropped to 1/5. In conclusion, surface antiseptics without intervention of organic materials in the concentration range of 1/5 was achieved with this new disinfectant.

Keywords: Antimicrobial activity; Disinfectant; Germicide P; Hospital bacteria; Persulfate compound.

Received: June 27, 2006; **Accepted:** August 20, 2006

1. Introduction

The hospital environment serves as a reservoir for nosocomial pathogens and many

nosocomial infections (NIs) are likely to result from inadequate use of disinfectant followed by patient-to-patient transmission [1]. NIs remain a major global concern. Overall, national prevalence rates of NIs have been described as ranging between 3.5 and 9.9% [2], but they vary significantly between

*Corresponding author: Farzaneh Lotfipour, Faculty of Pharmacy, Tabriz University of Medical Sciences, Tabriz, Iran.
Tel: +98 (411) 3392580
Fax: +98 (411) 3344798
Email: lotfipoor@tbzmed.ac.ir

departments, patient groups, types of surgical procedures, and the use of different medical devices, etc. [1, 3, 4]. The most common NIs are lower respiratory tract infections, urinary tract infections, surgical-site infections, and primary septicemia [1, 5-7]. They lead to additional days of hospital stay and treatment [8-10], increased risk of death [11], and treatment costs [1, 12, 15]. The overall financial burden incurred by NIs has been estimated to be remarkable, for example: \$4.5 billion per year in the United States alone [1, 2]. Approximately one-third of all NIs are regarded as preventable by disinfection using sufficient disinfectant products [16]. High-level disinfection is a key measure in the control of hospital-acquired infections. Several products can serve this objective, and selection depends on efficiency, security and cost [2]. Germicide-P[®] is a newly formulated disinfectant product based on persulfate salts (Fazel Derakhshan Co., Iran). According to the company's preliminary investigations, Germicide-P[®] has shown to be an effective disinfectant in veterinary applications. The purpose of this study was to determine the *in vitro* germicidal activity of Germicide-P[®] against some hospital bacterial isolates.

2. Materials and methods

2.1. Bacterial strains

The following standard strains as well as clinical isolates were obtained from blood cultures or urine specimens from Sina Hospital of Tabriz, Iran: *Pseudomonas aeruginosa* (25 clinical isolates), *P. aeruginosa* (ATCC 9027), *Escherichia coli* (25 clinical isolates), *E. coli* (ATCC 10536), *Staphylococcus aureus* (25 clinical isolates) and *S. aureus* (ATCC 6538). All of the test organisms were identified using USP standard identification methods and preserved at -20 °C until the assays were performed.

2.2. Disinfectant product

Germicide-P[®] (Fazel Derakhshan Pharmaceutical Co., Iran) supplied as stock product. The dilutions of 1:5, 1:10, 1:20, 1:40 and 1:80 from Germicide-P[®] were prepared using sterile distilled water as diluents.

2.3. Antimicrobial evaluation tests

The antibacterial activity of Germicide-P[®] was monitored by standard suspension test in 5, 15, 30, 60 and 120 min. contact times using 0.5 McFarland concentration of each bacterial strain and minimum bactericidal concentrations (MBC) were determined at different exposure times and various dilutions [17, 18]. Also to determine the effect of organic materials on the disinfectant efficacy of Germicide-P[®], the same disinfectant test was carried out in the presence of 5 % bovine serum albumin.

2.4. Surface test

Surface test was performed according to Association of Official Analytical Chemists (AOAC) use-dilution method [19]. Briefly, stainless steel ring carriers were inoculated by soaking them in a 48 h broth culture with 10⁷ to 10⁸ cfu/ml of each bacterial strain for 15 min., yielding 10⁵ to 10⁶ cfu/carrier. The carriers were removed with a hooked inoculating needle and allowed to dry for 40 min. at 36±1 °C in Petri dish matted with two filter paper sheets. After drying, the inoculated carriers were placed individually into the disinfectant and exposed for 15 min. The rings were removed carefully and placed into tubes containing 10 ml of neutralizing broth (Lethen Broth/DIFCO). After 20 min., each carrier was removed to other new tubes with the same culture broth, in order to assure the neutralizing process. All tubes were incubated at 36±1 °C for 48 h. Fifteen carriers were used for each experiment. *P. aeruginosa* (ATCC 9027), *E. coli* (ATCC 10536) and *S. aureus* (ATCC 6538) were included in the

Table 1. Mean percentage of test strains growth after various contact times with Germicide-P®.

Test strains (Clinical isolates)	Contact time (min.)	Mean bacterial growth in serial dilutions of Germicide-P® (%)			
		1:5	1:10	1:20	1:40
<i>P. aeruginosa</i>	5	0	0	100	100
	15	0	0	80	100
	30	0	0	75	100
	60	0	0	72	100
	120	0	0	71	100
<i>S. aureus</i>	5	0	0	81	100
	15	0	0	68	100
	30	0	0	64	100
	60	0	0	60	100
	120	0	0	60	100
<i>E. coli</i>	5	0	0	53	100
	15	0	0	43	100
	30	0	0	29	100
	60	0	0	27	100
	120	0	0	27	100

study as the reference strains. The performance standard of the method is: Only 1 positive/15 replicates of carriers is admitted to consider that the disinfectant is efficient to kill the test bacteria. Isolates showing two or more positive carriers were considered less susceptible to the disinfectant than the reference strain [18, 19].

3. Results

3.1. Minimum bactericidal concentration (MBC) of Germicide-P®

Table 1 shows the results of serial dilution test to determine MBC of Germicide-P® against the selected bacterial strains at different exposure times.

3.2. Activity of Germicide-P® in the surface test condition

The results of experiment to show the effectiveness of Germicide-P® to kill the selected bacterial isolates in the surface tests are presented in Table 2.

3.3. The influence of organic materials on disinfectant activity of Germicide-P®

To determine the effect of organic materials on the disinfectant efficacy of Germicide-P®

against standard bacterial strains of *P. aeruginosa* (ATCC 9027), *E. coli* (ATCC 10536) and *S. aureus* (ATCC 6538), the disinfectant test in the presence of 5 % BSA was carried out and the results are summarized in Table 3.

4. Discussion

The main aim of the application of disinfectants in hospital environments is to reduce the risk of endemic and epidemic nosocomial infections in patients. A great number of disinfectants are used in the health care settings with various advantages and disadvantages [1]. Germicide-P®, a new disinfectant formulated based on persulfate salts, was evaluated in this study for its disinfectant effectiveness. The strains of *E. coli*, *S. aureus* and *P. aeruginosa* used in this study are the ones proposed in the European Standard UNE-EN 1276 [20] for the evaluation of bactericidal activity of chemical disinfectants and antiseptics used in food, industrial, domestic and institutional areas. According to the experiments to determine the contact time and MBC of germicide-P®, the 1:10 dilution of Germicide-P® in sterile water was effective after 5 min. contact time in the case of all isolates, whereas 1:20 dilution killed 47 and 19 % of *E. coli* and *S. aureus*

Table 2. The killing effect of Germicide-P® in the surface test condition.

Test strains	No. of clinical isolates	Susceptibility of bacterial strains in serial dilutions of Germicide-P® (%)		
		1:5	1:10	1:20
		<i>P. aeruginosa</i>	25	76
<i>S. aureus</i>	25	98	94	79
<i>E. coli</i>	25	86	74	68

isolates, respectively, and failed to kill any of *P. aeruginosa* isolates after 5 min. Only 73, 40 and 29 % killing was achieved after 120 min for *E. coli*, *S. aureus* and *P. aeruginosa*, respectively, indicating the more susceptibility of *E. coli* and *S. aureus* to Germicide-P® compared to *P. aeruginosa*.

Gram-negative bacteria are generally less susceptible to biocides than Gram-positive species. Such resistance is likely to be intrinsic, due to outer membrane that acts as a protective barrier. Due to the capacity of surviving in unfavorable environmental conditions and to the high resistance to antibiotic agents, antiseptics and disinfectants, *P. aeruginosa* continues to be an important pathogen in hospital acquired infections, mainly respiratory and urinary infections. The transmission of this bacterium is almost always related to contamination of medical-surgical instruments and respiratory apparatus [19]. Vess and co-workers [21] demonstrated that *Pseudomonas* spp. survive during long periods on the surfaces of polyvinyl chloride (PVC) pipes, showing tolerance to the treatment with different disinfectants (synthetic phenols, QACs, formaldehyde and chlorine), and could become a potent reservoir of microbial contamination. Fernández-Astorga and colleagues [22] have reported that the high resistance of *Pseudomonas* spp. to cationic agents seems to be associated with the chemical composition of the external membrane. Our study also demonstrated that *P. aeruginosa* strains were more resistant to the tested disinfectant.

Hospital isolates of gram-negative bacteria belonging to the *Enterobacteriaceae* family, such as *Klebsiella*, *Enterobacter*, *Serratia*

and *Proteus*, have shown resistance to disinfectants, mainly quaternary ammonium compounds and phenols [19]. However, according to a study done by Guimaraes and coworkers [19] as well as Homand and colleagues [23] *E. coli* strains were more susceptible to disinfectants than other *Enterobacteriaceae* tested. The results of our study also were in good agreement with the previous findings and our *E. coli* strains showed more susceptibility to the Germicide-P®.

There are several reasons for testing hospital-acquired pathogens in the surface test; the most important one is that biocides are well known to be less effective on surfaces than in suspension although surface disinfection may well be the more clinically relevant process [19]. Based on the results of surface test of Germicide-P®, the antibacterial efficacy of Germicide-P® on the selected strains was remarkably modified in which 100% susceptibility of all three bacteria in 1/5 dilution decreased to 76, 98 and 86% in the case of *P. aeruginosa* and *S. aureus* and *E. coli*, respectively. However, the activity of Germicide-P® was not significantly influenced by the added organic load, according to the figures pertaining to the additional organic load test and the differences between MBC of Germicide-P® with and without organic load are meaningless indicating that the mechanism of antibacterial activity of this disinfectant is not remarkably influenced by the presence of organic materials.

In conclusion, germicide P® found to be a promising product with the MBC of 1/5 after 5 min against all of the tested bacteria at the room temperature in *in vitro* condition and *E. coli* isolates were the most susceptible isolates and surface antisepsis without intervention of

Table 3. Mean percentage of test strains growth with and without BSA in the contact time of 15 min.

Test strains	Mean bacterial growth (%) at different Germicide-P® dilutions			
	1:5 / 1:5 _D *	1:10 / 1:10 _D	1:20 / 1:20 _D	1:40 / 1:40 _D
<i>P. aeruginosa</i>	0 / 0	0 / 0	80 / 76	100 / 100
<i>S. aureus</i>	0 / 0	0 / 0	68 / 69	100 / 100
ATCC 6538				
<i>E. coli</i>	0 / 0	0 / 0	43 / 43	100 / 100
ATCC 10536				

* D: Dirty conditions of 5 % bovine serum albumin.

organic materials in the same concentration range was achieved with this new disinfectant.

Acknowledgments

This project was financially supported by Fazel Derakhshan Pharmaceutical Co. (Tehran, Iran). Also authors would like to express their appreciations to the ordinators of Drug Applied Research Center of Tabriz University of Medical Sciences which permitted this project to be carried out in this Research Center.

References

- [1] Kampf G, Kramer A. Epidemiologic background of hand hygiene and evaluation of the most important agents for scrubs and rubs. *Clin Microbiol Rev* 2004; 17: 863-93.
- [2] Jarvis WR. Selected aspects of the socioeconomic impact of nosocomial infections: Morbidity, costs, and prevention. *Infect Control Hosp Epidemiol* 1996; 17: 552-7.
- [3] Anonymous. National nosocomial infections surveillance (NNIS) system report, data summary from January 1992-June 2002. *Am J Infec Control* 2002; 30: 458-75.
- [4] Gaynes RP, Culver DH, Horan TC, Edwards JR, Richards C, Tolson JS. Surgical site infection (SSI) rates in the United States, 1992-1998: The national nosocomial infections surveillance system basic SSI risk index. *Clin Infect Dis* 2001; 33:S69-S77.
- [5] Astagneau P, Rioux C, Golliot F, Brucker G. Morbidity and mortality associated with surgical site infections: Results from the 1997-1999 INCISO surveillance. *J Hosp Infect* 2001; 48: 267-74.
- [6] Gastmeier P, Kampf G, Wischniewski N, Hauer T, Schulgen G, Schumacher M, Daschner F, Rütten H. Prevalence of nosocomial infections in representative German hospitals. *J Hosp Infect* 1998; 38: 37-49.
- [7] Soletto L, Pirard M, Boelaert M, Peredo R, Vargas R, Gianella A, van der Stuyft P. Incidence of surgical site infections and the validity of the National Nosocomial Infections Surveillance System risk index in a general surgical ward in Santa Cruz, Bolivia. *Infect Control Hosp Epidemiol* 2003; 24: 26-30.
- [8] Foxman B. Epidemiology of urinary tract infections: Incidence, morbidity, and economic costs. *Am J Med* 2002; 113: 5S-13S.
- [9] Jenney AW, Harrington GA, Russo PL, Spelman DW. Cost of surgical site infections following coronary artery bypass surgery. *A N Z J Surg* 2001; 71: 662-4.
- [10] Olaechea PM, Ulibarrena MA, Álvarez-Lerma F, Insausti J, Palomar M, de la Cal MA. Factors related to hospital stay among patients with nosocomial infection acquired in the intensive care unit. *Infect Control Hosp Epidemiol* 2003; 24: 207-13.
- [11] Garcia-Martin M, Lardelli-Claret P, Jiménez-Moleón JJ, Bueno-Cavanillas A, Luna-del-Castillo JD, Gámez-Vargas R. Proportion of hospital deaths potentially attributable to nosocomial infections. *Infect Control Hosp Epidemiol* 2001; 22: 708-14.
- [12] Hollenbeak CS, Murphy D, Dunagan WC, Fraser VJ. Nonrandom selection and the attributable cost of surgical-site infections. *Infect Control Hosp Epidemiol* 2002; 23: 177-82.
- [13] Orsi GB, Di Stefano L, Noah N. Hospital-acquired, laboratory-confirmed bloodstream infection: Increased hospital stays and direct costs. *Infect Control Hosp Epidemiol* 2002; 23:190-7.
- [14] Reilly J, Twaddle S, McIntosh J, Kean L. An economic analysis of surgical wound infection. *J Hosp Infect* 2001; 49: 245-9.
- [15] Whitehouse JD, Friedman D, Kirkland KB, Richardson WJ, Sexton DJ. The impact of surgical-site infections following orthopedic surgery at a community hospital and a university hospital: Adverse quality of life, excess length of stay, and extra costs. *Infect Control Hosp Epidemiol* 2002; 23:183-9.
- [16] Haley RW, Culver DH, White JW, Morgan WM,

- Emori TG, Van Munn P, Hooton TM. The efficacy of infection surveillance and control programs in preventing nosocomial infections in US hospitals. *Am J Epidemiol* 1985; 121:182-205.
- [17] Russell AD, Hugo WB, Ayliffe GAJ. *Principles and practice of disinfection, preservation and sterilization*. Blackwell Scientific Publication, London, 1982: pp. 8-106.
- [18] Vizcaino-Alcaide MJ, Herruzo-Cabrera R, Fernández-Acena MJ. Comparison of the disinfectant efficacy of perasafe and 2% glutaraldehyde in *in vitro* tests. *J Hosp Infect* 2003; 53: 124-8.
- [19] Guimarães MA, Tibana A, Nunes MP, Santos KR. Disinfectant and antibiotic activities: A comparative analysis in Brazilian hospitals bacterial isolates. *Braz J Microbiol* 2000; 31: 196-9.
- [20] Deza MA, Araujo M, Garrido MJ. Inactivation of *Escherichia coli*, *Listeria monocytogenes*, *Pseudomonas aeruginosa* and *Staphylococcus aureus* on stainless steel and glass surfaces by neutral electrolysed water. *Lett Appl Microbiol* 2005; 40: 341-6.
- [21] Vess RW, Anderson RL, Carr JH, Bond WW, Favero MS. The colonization of solid PVC surfaces and the acquisition of resistance to germicides by water micro-organisms. *J Appl Bacteriol* 1993; 74: 215-21.
- [22] Fernandez-Astorga A, Hijarrubia MJ, Hernandez M, Arana I, Sunen E. Disinfectant tolerance and antibiotic resistance in psychrotrophic gram-negative bacteria isolated from vegetables. *Lett Appl Microbiol* 1995; 20:308-11.
- [23] Hammond SA, Morgan JR, Russell AD. Comparative susceptibility of hospital isolates of gram-negative bacteria to antiseptics and disinfectants. *J Hosp Infect* 1987; 9: 255-64.